Chemoprevention and vaccines: A review of the nonsurgical options for the treatment of cervical dysplasia

International Journal of Gynecological Cancer

Volumn 15, Issue 1, 2005, Pages 4-12

  Bell, Maria C ^a,c   Alvarez, R D ^b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NONE   (United States)

Author keywords

Chemoprevention; Human papillomavirus; Vaccine

Indexed keywords

3 INDOLEMETHANOL; ALITRETINOIN; ASCORBIC ACID; BETA CAROTENE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DNA VACCINE; EFLORNITHINE; FENRETINIDE; FOLIC ACID; ISOTRETINOIN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PLACEBO; PROTEIN E6; PROTEIN E7; RETINOIC ACID; RETINOL; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR; WART VIRUS VACCINE; ZYC 101;

ANTIBODY PRODUCTION; ARTHRALGIA; BLOATING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG TOLERABILITY; EXCISION; HEADACHE; HUMAN; IMMUNE RESPONSE; NAUSEA; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; REVIEW; SKIN BRUISING; TREATMENT OUTCOME; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VIRUS PARTICLE; VOMITING; WART VIRUS;

CANCER VACCINES; CHEMOPREVENTION; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL DYSPLASIA; VACCINES; VIRAL VACCINES;

EID: 13244295439     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2005.15002.x     Document Type: Review

References (52)

1. Sexually Transmitted Disease Surveillance for 1996. Atlanta: United States Department of Health and Human Services, Centers for Disease Control and Prevention, 1997.
2. Tracking the Hidden Epidemic 2000. Trends in STDs in the U.S. In: Centers for Disease Control, 2000.
3. Larsen N. Invasive cervical cancer arising in young white females. J Natl Cancer Inst 1994;86:6-7.
4. Jones H. The Bethesda System. Cancer 1995;75:1914.
5. Solomon D, Frable WJ, Vooijs GP et al. ASCUS and AGUS criteria. International Academy of Cytology Task Force summary. Diagnostic and cytology towards the 21st century: an international expert conference and tutorial. Acta Cytol 1998;42:16-24.
6. Butterworth CE Jr, Hatch KD, Gore H, Mueller H, Krumdieck CL. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am J Clin Nutr 1982;35:73-82.
7. Butterworth CE Jr, Hatch KD, Macaluso M et al. Folate deficiency and cervical dysplasia. JAMA 1992;267:528-33.
8. Butterworth CE Jr, Hatch KD, Soong SJ et al. Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am J Obstet Gynecol 1992;166:803-9.
9. Childers JM, Chu J, Voigt LF et al. Chemoprevention of cervical cancer with folic acid: a phase III Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev 1995;4:155-9.
10. de Vet HC, Knipschild PG, Willebrand D, Schouten HJ, Sturmans F. The effect of beta-carotene on the regression and progression of cervical dysplasia: a clinical experiment. J Clin Epidemiol 1991;44:273-83.
11. Manetta A, Schubbert T, Chapman J et al. beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomarkers Prev 1996;5:929-32.
12. Keefe KA, Schell MJ, Brewer C et al. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 2001;10:1029-35.
13. Romney SL, Ho GY, Palan PR et al. Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 1997;65:483-92.
14. Mackerras D, Irwig L, Simpson JM et al. Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer 1999;79:1448-53.
15. Bell MC, Crowley-Nowick P, Bradlow HL et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000;78:123-9.
16. Surwit EA, Graham V, Droegemueller W et al. Evaluation of topically applied retinoic acid in the treatment of cervical intraepithelial lesions. Am J Obstet Gynecol 1982;143:821-3.
17. Meyskens FL Jr, Graham V, Chvapil M, Dorr RT, Alberts DS, Surwit EA. A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. J Natl Cancer Inst 1983;71:921-5.
18. Romney SL, Dwyer A, Slagle S et al. Chemoprevention of cervix cancer: Phase I-II. A feasibility study involving the topical vaginal administration of retinyl acetate gel. Gynecol Oncol 1985;20:109-19.
19. Weiner SA, Surwit EA, Graham VE, Meyskens FL Jr. A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy. Invest New Drugs 1986;4:241-4.
20. Meyskens FL Jr, Surwit E, Moon TE et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 1994;86:539-43.
21. Pollen M, Atkinson EN, Schottenfeld D et al. A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 2001;7:3356-65.
22. Alvarez RD, Conner MG, Weiss H et al. The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol Biomarkers Prev 2003;12:114-9.
23. Kim S, Park T, Kwon J. 13-cis-retinoic acid for chemoprevention after colpoconization for cervical intraepithelial neoplasia. Int J Gynaecol Obstet 2003;81:217-8.
24. Mitchell MF, Tortolero-Luna G, Lee JJ et al. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res 1998;4:303-10.
25. Powell MA, Pfeifer JD, Buttin BS, Gibb RK, Luck MB, Rader JS. A pilot study of celecoxib in the treatment of patients with cervical and vaginal intraepithelial neoplasia. In: ASCO Annual Meeting (Abstract 1830), 2003.
26. Werness B, Levine A, Howley P. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
27. Dyson N, Howley P, Munger K et al. The human papillomavirus-E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-40.
28. Crish J, Bone F, Balasubramanian S et al. Suprabasal expression of the human papillomavirus type 16 oncoproteins in mouse epidermis alters expression of cell cycle regulatory proteins. Carcinogenesis 2000;21:1031-7.
29. Durst M, Glitz D, Schneider A et al. Human papillomavirus type 16 (HPV16) gene expression and DNA replication in cervical neoplasia; analysis by in situ hybridization. Virology 1992;189:132-40.
30. Harro C, Pang Y, Roden R et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16, L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-92.
31. Suzick J, Ghim S, Palmer-Hill P et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci 1995;92:11553-7.
32. Breitburd F, Kirnbauer R, Hubbert N et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
33. Campo M, Grindlay G, O'Neil B, Chandrachud L, McGarvie G, Jarrett W. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 1993;74:945-53.
34. Koutsky L, Ault K, Wheeler C et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
35. Muller M, Zhou J, Reed T et al. Chimeric papillomavirus-like particles. Virology 1997;234:93-111.
36. Greenstone H, Nieland J, DeVisser K et al. Chimeric papillomavirus virus-like particles elicit antitumour immunity against the E7 oncoprotein in an HPV 16 tumour model. Proc Natl Acad Sci 1998;95:1800-5.
37. Villa L, Costa R, Petta C et al. A dose-ranging safety and immunogenicity study of a quadrivalent HPV (types 6/ 11/16/18) L1 VLP vaccine in women. In: 20th International Papillomavirus Conference, Paris, France, 2002.
38. Boursarghin L, Combita A, Touze A. Immunization with HPV L1 VLPs induced cross-neutralizing antibodies. In: 20th International Papillomavirus Conference, Paris, France, 2002.
39. Frisch M, Biggar R, Goedert J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-10.
40. Seshadri L, George S, Vasudevan B, Krishna S. Cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant recipients. Indian J Cancer 2001;38:92-5.
41. + lymphocytes are recruited to the dysplastic cervix. J Clin Immun 1995;15:130-6.
42. Kast W, Brandt R, Drijfhout J, Melief C. Human leukocyte antigen A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16, E6 and E7 proteins identified by using the processing-defective human cell in T2. J Immunother 1993;14:115-20.
43. Ressing M, Sette A, Brandt R et al. Human CTL epitopes encoded by human papillomavirus type 16, E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995;154:5934-43.
44. Ressing M, Driel WV, Brandt R et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000;23:255-66.
45. Muderspach L, Wilczynski S, Roman L et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6:3406-16.
46. Cheng W, Hung C, Pai S et al. Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. J Biomed Sci 2002;9:675-87.
47. + T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003;21:4036-42.
48. Klencke B, Matijevic M, Urban R et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002;8:1028-37.
49. Borysiewicz L, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1498-9.
50. Steinman R. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
51. Santin A, Hermonat P, Ravaggi A et al. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999;73:5402-10.
52. Ferrara A, Norm M, Sehr P et al. Dendritic cell-based tumor vaccine for cervical cancer II. Results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003;129:521-30.